Navigation Links
Phase I Pro-Vas® Effectiveness Study Presented at AUA Meeting
Date:6/8/2011

WASHINGTON, June 8, 2011 /PRNewswire/ -- A new clinical study presented at the American Urological Association (AUA) Annual Meeting shows the less-invasive Pro-Vas® occlusion as a highly promising method of permanent male sterilization.

The clinical study results were presented by Douglas A. Swartz, M.D., to a physician audience at the AUA Annual Meeting. The AUA meeting is the world's largest gathering of urologists each year. Dr. Swartz is a private-practice urologist in Jacksonville, Fla. He served as lead investigator for the 15-month clinical study that involved 29 patients.

Dr. Swartz said the Pro-Vas technique is the least invasive – and most effective – form of vasectomy available to men today.

More than 500,000 vasectomies are performed annually in the United States. Traditional vasectomy involves the cutting and cauterizing of both sperm ducts, which causes pain and swelling post surgery. The new Pro-Vas occlusion technique studied by Dr. Swartz, on the other hand, utilizes an easy-to-apply, titanium spring ligation clip that stops the flow of sperm without the need to cut or burn the sperm ducts.

In addition to its initial high effectiveness rate, Pro-Vas also was noted to result in less post-procedure pain and quicker return to normal activities compared with traditional vasectomy. Additionally, there were no complications following Pro-Vas occlusions, but it is acknowledged the number of patients is not sufficient to provide statistically significant results.

"The Pro-Vas occlusion technique has the potential to simplify and standardize the vasectomy technique," Dr. Swartz said. "It may provide less experienced vasectomy surgeons a means for achieving clinical results similar to those of experienced surgeons. The Pro-Vas technique also spares sacrificing the vasal artery."

Dr. Swartz added that there should be a lower recanalization rate with the Pro-Vas method because the spring ligation clip cannot dislodge or ever lose its constant low-pressure occlusion force. Additionally, the clip is designed not to apply so much pressure that tissue death (necrosis) results – a situation that sometimes occurs with other types of ligatures.

"Should the patient ever change his mind with regard to his vasectomy, reversal of the Pro-Vas procedure should be much easier as the clip is very easy to identify and dissection to find the two occluded ends of the vas will be much simpler," Dr. Swartz said.

Patient acceptance may be higher with the Pro-Vas occlusion technique than traditional vasectomy because overall quality of the outcomes may be improved, according to Dr. Swartz.

"If these hypotheses are later confirmed by additional clinical studies, then there may be significant economies for the healthcare system at-large to be gained from Pro-Vas," Dr. Swartz concluded.

About MenRx Surgical

MenRx Surgical, a portfolio company of Gyrx LLC, markets an innovative new male contraceptive medical device using vas-occlusive technology. The device – Pro-Vas® – now competes in the global male contraceptive market, which formerly included only condoms and the traditional vasectomy surgical procedure. Pro-Vas provides permanent contraception for men by occluding the vas deferens with the specially designed, atraumatic clip. The Pro-Vas approach increases male birth control accountability, decreases pain and swelling, and reduces post-procedure recovery time. Learn more about Pro-Vas at: www.GetTheClip.com. Media contact: Scott D. Olson, phone: (855) 477-6827 (855-4-PRO-VAS)

MenRx Surgical Media Relations Contact:
Scott D. Olson
Phone: (855) 477-6827
E-mail: solson@pro-vas.com
www.pro-vas.com


'/>"/>
SOURCE MenRx Surgical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical ... heart failure, today announced that it intends to offer shares ... an underwritten public offering.  The offering is subject to market ... to whether or when the offering may be completed, or ...   --> --> Roth ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
(Date:2/9/2016)... This TforG report includes the Surgical Procedures Database with ... in South Korea . To add ... written and numerical analysis on the current trends, size, ... latest reforms of the local Healthcare system are clearly ... The report helps businesses gain a unique insight into ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... them of the lives they’ve led and the people they’ve touched. , That’s ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling ... handle, you are not alone. According to the Center for Disease Control and Prevention ... type 2 diabetes and certain types of cancer, some of the leading causes of ...
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):